J Irani

Summary

Affiliation: CHU de Poitiers
Country: France

Publications

  1. ncbi [Urothelial tumors]
    Jacques Irani
    Prog Urol 14:957, 959-96. 2004
  2. ncbi [Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma]
    Jacques Irani
    Service d'Urologie, , Poitiers, France
    Prog Urol 17:996. 2007
  3. ncbi Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia
    J Irani
    Department of Urology, Centre Hospitalier Universitaire La Miletrie, Poitiers, France
    BJU Int 91:482-4. 2003
  4. ncbi Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial
    Jacques Irani
    Urology Unit, University Hospital, Poitiers, France
    Lancet Oncol 11:147-54. 2010
  5. ncbi [Clinical practice guidelines (CPG): are they useful? Example of the benign prostatic hyperplasia (BPH)]
    J Irani
    Service d Urologie, CHU La Miletrie, 2, rue de la Miletrie, 86000 Poitiers, France
    Ann Urol (Paris) 38:S19-23. 2004
  6. ncbi Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection
    Jacques Irani
    Department of Urology, Poitiers University Hospital, Poitiers, France
    Urology 65:533-7. 2005
  7. ncbi [Bladder cancer: news in 2008]
    J Irani
    Service d Urologie, CHU La Miletrie, 2 rue de la Miletrie, Poitiers Cedex, France
    Prog Urol 18:S125-9. 2008
  8. ncbi [Structure of a medical article]
    J Irani
    Service d Urologie, CHU La Miletrie, avenue Jacques Coeur, 86000 Poitiers, France
    Ann Urol (Paris) 39:S164-8. 2005
  9. ncbi [Follow-up of urothelial tumours. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie]
    Jacques Irani
    Comite Tumeurs Urothéliales du CCAFU
    Prog Urol 15:581-6. 2005
  10. ncbi [Management of Ta, T1, and in situ bladder carcinoma: what is new?]
    Jacques Irani
    Service d Urologie, CHU La Miletrie, 86000 Poitiers
    Prog Urol 18:S94-8. 2008

Detail Information

Publications68

  1. ncbi [Urothelial tumors]
    Jacques Irani
    Prog Urol 14:957, 959-96. 2004
  2. ncbi [Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma]
    Jacques Irani
    Service d'Urologie, , Poitiers, France
    Prog Urol 17:996. 2007
  3. ncbi Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia
    J Irani
    Department of Urology, Centre Hospitalier Universitaire La Miletrie, Poitiers, France
    BJU Int 91:482-4. 2003
    ..To analyse the relationship between obesity and prostate cancer, when compared with men with benign prostatic hyperplasia (BPH)...
  4. ncbi Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial
    Jacques Irani
    Urology Unit, University Hospital, Poitiers, France
    Lancet Oncol 11:147-54. 2010
    ..We designed a randomised double-blind trial to compare the efficacy of three drugs, each of which has proven effective for preventing hot flushes in previous studies...
  5. ncbi [Clinical practice guidelines (CPG): are they useful? Example of the benign prostatic hyperplasia (BPH)]
    J Irani
    Service d Urologie, CHU La Miletrie, 2, rue de la Miletrie, 86000 Poitiers, France
    Ann Urol (Paris) 38:S19-23. 2004
    ..A potential solution may require a deeper involvement of the learned urologic society in the drafting and distribution of the CPG...
  6. ncbi Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection
    Jacques Irani
    Department of Urology, Poitiers University Hospital, Poitiers, France
    Urology 65:533-7. 2005
    ....
  7. ncbi [Bladder cancer: news in 2008]
    J Irani
    Service d Urologie, CHU La Miletrie, 2 rue de la Miletrie, Poitiers Cedex, France
    Prog Urol 18:S125-9. 2008
    ..Finally, new radiochemotherapy protocols have appeared for infiltrating bladder tumors. Extended lymphadenectomy and laparoscopy were also evaluated in detail...
  8. ncbi [Structure of a medical article]
    J Irani
    Service d Urologie, CHU La Miletrie, avenue Jacques Coeur, 86000 Poitiers, France
    Ann Urol (Paris) 39:S164-8. 2005
    ..A conclusion may finalize the discussion or form the subject matter for an independent section. Lastly, all articles include a relevant summary and a suitable bibliography...
  9. ncbi [Follow-up of urothelial tumours. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie]
    Jacques Irani
    Comite Tumeurs Urothéliales du CCAFU
    Prog Urol 15:581-6. 2005
    ....
  10. ncbi [Management of Ta, T1, and in situ bladder carcinoma: what is new?]
    Jacques Irani
    Service d Urologie, CHU La Miletrie, 86000 Poitiers
    Prog Urol 18:S94-8. 2008
    ..In addition, intravesical BCG significantly reduces the risk of progression after transurethral resection in patients with nonmuscle-invasive bladder cancer who receive maintenance treatment...
  11. ncbi [The 20-core prostate biopsy protocol: a new gold standard?]
    J Irani
    Service d Urologie, CHU La Miletrie, rue de la Miletrie, 86000 Poitiers, France
    Prog Urol 18:251-2. 2008
  12. ncbi ["Superficial bladder cancers" do not exist anymore]
    J Irani
    Service d Urologie, CHU La Miletrie, 86000 Poitiers, France
    Prog Urol 18:204-5. 2008
    ..The French Oncologic Society proposes to designate by non-infiltrating bladder neoplasm by the muscle Ta, T1 and Tis tumours...
  13. ncbi [PCPT trial: expected bias and their management]
    J Irani
    Service d Urologie de l Hôpital La Milétrie, Université Poitiers, CHU Poitiers, France
    Prog Urol 18:S44-6. 2008
    ..Analysis of the sources of bias led to the conclusion that systematic end of trial biopsies constituted the most robust end point...
  14. ncbi [International comparison of guidelines for the management of benign prostatic hyperplasia: use of a validated generic tool]
    Jacques Irani
    Service d Urologie, CHU La Miletrie, Poitiers, France
    Prog Urol 14:29-32. 2004
    ..methodologies of development of CPG and their content using a validated tool...
  15. ncbi [Relevance of chemoprevention from PCPT trial]
    J Irani
    Service d Urologie de l Hôpital La Milletrie, Université Poitiers, CHU Poitiers, France
    Prog Urol 18:S63-5. 2008
    ....
  16. ncbi [Upper urinary tract tumor: conservative treatment of localized forms]
    Jacques Irani
    Service d'Urologie, , 86000 Poitiers
    Prog Urol 13:555-9. 2003
  17. ncbi Renal tumor size: comparison between computed tomography and surgical measurements
    J Irani
    Department of Urology, Centre Hospitalier Universitaire La Miletrie, F 86000 Poitiers, France
    Eur Urol 39:300-3. 2001
    ..We studied the agreement between renal tumor size as assessed on computed tomography (CT) before surgery and that measured during histopathological examination on the radical nephrectomy specimen...
  18. ncbi Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer
    F Saint
    Department of Urology, , , France
    Urology 57:617-21; discussion 621-2. 2001
    ..Prospective randomized studies are required to evaluate leukocyturia as a basis on which to adapt the BCG instillation schedule to individual patient susceptibility...
  19. ncbi [Efficiency and tolerance of intermittent self-dilatation after internal urethrotomy for urethral strictures]
    A Rouanet
    Service d Urologie, CHU La Miletrie, Poitiers, France
    Prog Urol 21:955-60. 2011
    ..To retrospectively evaluate efficiency and tolerance of intermittent self-dilatation (ISD) after unicenter internal urethrotomy (IU) on urethral strictures (US)...
  20. ncbi [Survival is associated with time to reach PSA nadir (DAN) and the ratio DAN/nadir value after androgen deprivation for prostate cancer]
    A Gagnat
    Service d Urologie, CHU La Miletrie, 2, rue de la Miletrie, 86000 Poitiers, France
    Prog Urol 21:341-8. 2011
    ..The objective of this study was to assess the prognostic decrease rate of PSA in patients treated with androgen suppression (AS) for prostate cancer (PCa)...
  21. ncbi [Diagnosis and management of adverse events occuring during BCG therapy for non-muscle invasive bladder cancer (NMIBC): Review of the Cancer Committee of the French Association of Urology]
    Y Neuzillet
    Service d Urologie, Faculte de Medecine Paris Ile de France Ouest, Universite de Versailles Saint Quentin en Yvelines, Hopital Foch, 40, rue Worth, 92150 Suresnes, France Electronic address
    Prog Urol 22:989-98. 2012
    ..In practice, adverse events (AEs) of BCG therapy could restrict its prescription by urologists. The aim of this article was to present a review of these AEs and of their management...
  22. ncbi [Surgical management of urinary tract endometriosis: 12 cases]
    B Tisserand
    Service d Urologie, CHU Jean Bernard, 2, rue de la Miletrie, 86000 Poitiers, France
    Prog Urol 19:850-7. 2009
    ..Our study aimed at evaluating, retrospectively, the outcome of the surgical management of urinary tract endometriosis...
  23. ncbi [Variation of urinary PCA3 following transrectal ultrasound-guided prostate biopsy]
    Y Prezelin
    Département d urologie, Centre Hospitalier Universitaire, Poitiers, France
    Prog Urol 21:412-6. 2011
    ..Serum PSA is known to rise slightly following an attentive digital rectal examination (DRE) and dramatically following prostatic biopsy. The aim of this study was to evaluate the PCA3 response in these situations...
  24. ncbi [T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a/T1b). A multicenter study by the French Urological Association (CCAFU)]
    B Faivre d'Arcier
    Service d Urologie, Hopital Bretonneau, CHU de Tours, 2, boulevard Tonnelle, 37000 Tours, France
    Prog Urol 20:440-9. 2010
    ..The aim of this multicenter study was to determine the prognostic value of the depth of invasion of lamina propria and more specifically the influence of the invasion of the muscularis mucosae on survival parameters in T1 bladder carcinoma...
  25. ncbi [Short or long schemes of antibiotic prophylaxis for prostate biopsy. A multicentre prospective randomised study]
    R Briffaux
    Service d Urologie, CHU La Miléterie, 2, rue de La Miléterie, 86021 Poitiers Cedex, France
    Prog Urol 19:39-46. 2009
    ..We compared the incidence of the Urinary Tract Infection between a single preoperative dose and a three-day antibiotic prophylaxis regimen for transrectal ultrasound guided biopsy in randomized multicenter trial...
  26. ncbi [French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)]
    N Gaunez
    Service d Urologie, CHU de Poitiers, 2, rue de la Miletrie, 86000 Poitiers, France
    Prog Urol 22:350-3. 2010
    ..Translation and linguistic validation of the French version of Bladder Cancer Index (BCI)...
  27. ncbi [Open partial nephrectomy: standard of minimal invasive surgery]
    J C Dezael
    Service d Urologie, CHU de Poitiers, France
    Prog Urol 21:917-24. 2011
    ..The oncological results are comparable to those obtained by total nephrectomy, while preserving kidney function. Our objective was to describe our experience and research factors associated with complications, recurrence and death...
  28. ncbi Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer
    F Saint
    Service d'Urologie, , , Lyon, France
    Urology 57:883-8. 2001
    ....
  29. ncbi [Pelvic lymph nodes dissection for prostate cancer: Minilap with speculum vs laparoscopy]
    B Merlet
    Service d Urologie, CHU de La Miletrie, 2, rue de la Miletrie, 86021 Poitiers Cedex, France
    Prog Urol 20:279-83. 2010
    ..Two techniques are available for PLND: minilap and laparoscopy. The purpose of this study was to compare retrospectively minilap and the 2 ways of laparoscopy: intra- and extraperitoneum, in terms of efficiency and complications...
  30. ncbi [Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate]
    C Nedelec
    Service de Neurologie, Centre Hospitalier de La Rochelle, Poitiers, France
    Prog Urol 19:47-53. 2009
    ..To evaluate secondary effects on cognitive functions as memory and attention impairments in men treated by androgen suppression for cancer of prostate...
  31. ncbi Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years
    J Patard
    Department of Urology, Centre Hospitalo-Universitaire Rennes, Rennes, France
    Urology 58:551-6. 2001
    ..Very accurate surgical and pathologic evaluations before treatment and lifelong follow-up are obviously required...
  32. ncbi [Percentage of positive biopsy cores at the onset of hormone therapy for prostate cancer: prognostic significance]
    G Normand
    Service d Urologie, CHU La Miletrie, 2, rue de la Miletrie, 86021 Poitiers Cedex, France
    Prog Urol 19:321-6. 2009
    ..We hypothesized that it would predict time to hormonal independence and survival in prostate cancer patients treated by androgen deprivation therapy (ADT)...
  33. ncbi [Seminal vesicle biopsies: Interest in the prostate cancer staging before radiation therapy or brachytherapy]
    R Braguet
    Service d Urologie, Hopital Bretonneau, CHU de Tours, 2 boulevard Tonnele, 37000 Tours, France
    Prog Urol 21:534-41. 2011
    ..Our main objective was to assess their contribution before radiation therapy or brachytherapy. Our secondary objective was to compare pathologic findings of the SVB to the magnetic resonance imaging's (MRI) results...
  34. ncbi Revisiting the immunophenotype of nephrogenic adenoma
    Gaelle Fromont
    Department of Pathology, CHU Universite de Poitiers, Poitiers, France
    Am J Surg Pathol 33:1654-8. 2009
    ....
  35. ncbi [Long-term follow-up of 88 patients operated for primary vesicorenal reflux in childhood]
    Benjamin Lecoq
    Service d Urologie, Hopital La Miletrie, Poitiers, France
    Prog Urol 14:167-71. 2004
    ..To determine the long-term outcome of patients operated for primary vesicorenal reflux (VRR) in childhood...
  36. ncbi [Percutaneous nephrolithotomy (PCNL) in subjects over the age of 70: a multicentre retrospective study of 210 cases]
    Bertrand Dore
    Service d Urologie, Hopital La Miletrie, Poitiers, France
    Prog Urol 14:1140-5. 2004
    ..However this technique is sometimes necessary for very large or complex stones in patients with several comorbidities...
  37. ncbi [Sensitivity of abdominal radiography without preparation compared with computed tomography in the assessment of residual fragments after percutaneous nephrolithotomy]
    Christophe Pires
    Service d Urologie, CHU La Miletrie, 86021 Poitiers
    Prog Urol 13:581-4. 2003
    ..The objective of this study was to evaluate the contribution of spiral CT to the immediate follow-up of percutaneous nephrolithotomy...
  38. ncbi [The French linguistic validation of the Ureteric Stent Symptom Questionnaire (USSQ)]
    A Puichaud
    Service d Urologie, CHU de Poitiers, rue de milétrie, 86000 Poitiers, France
    Prog Urol 20:210-3. 2010
    ..Translation and linguistic validation of the French version of the Ureteral Stent Symptom Questionnaire (USSQ)...
  39. ncbi [New concepts in management of NMIBC in 2010]
    G Pignot
    Service d Urologie, Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Prog Urol 21:S34-7. 2011
    ..Early cystectomy is the current option for BCG-refractory high risk bladder tumor. Rarely, some conservative options, such as endovesical chemotherapy, could be discussed at an individual level...
  40. ncbi Mesonephric remnant hyperplasia: an unusual benign mimicker of prostate cancer
    Mokrane Yacoub
    Services d anatomie pathologique, CHU Jean Bernard, rue de la Miletrie, 86000 Poitiers, France
    Ann Diagn Pathol 13:402-4. 2009
    ..The presence of MRs in prostate tissues may be more common than appreciated or reported. Once the possibility is considered, the diagnosis is easily confirmed using immunochemistry...
  41. ncbi [Repeat prostate biopsies following a first negative biopsy in a context of an elevated prostate specific antigen]
    A P Floc'h
    Service d Urologie, CHU de Poitiers, Poitiers, France
    Prog Urol 22:718-24. 2012
    ..The objective of this study was to analyze a group of patients who had a negative first BP for a PSA superior to 4 ng/mL and at least one additional PB and to compare these cases with controls who had the diagnosis PCa from the first PB...
  42. ncbi Percentage of positive biopsy cores at the onset of hormone therapy for prostate cancer: prognostic significance
    Guillaume Normand
    Department of Urology, Centre Hospitalier Universitaire, Poitiers, France
    Urol Int 83:160-5. 2009
    ..We hypothesized that it would predict time to hormonal independence and survival in prostate cancer patients treated with androgen deprivation therapy (ADT)...
  43. ncbi [Prognostic significance of "sawtooth" PSA and "stepwise" PSA]
    Olivier Celhay
    Service d Urologie, CHU de Poitiers, France
    Prog Urol 17:943-6. 2007
    ..To evaluate the risk of diagnosing prostate cancer on repeated biopsies in patients with fluctuating PSA values compared to patients with stable or regularly increasing PSA values...
  44. ncbi [Renal adenocarcinoma in a two and a half year old child: Diagnosis, therapeutic management and 10-year followup]
    Christophe Pires
    Service d Urologie, CHU La Miletrie, Poitiers, France
    Prog Urol 12:675-9. 2002
    ..The authors report the case of a two and a half year old child treated by surgery alone with a follow-up of 10 years without recurrence...
  45. ncbi BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder
    J Irani
    Service d Urologie et de Médecine Nucléaire, Centre Hospitalier Universitaire La Miletrie, Poitiers, France
    Eur Urol 35:89-92. 1999
    ..We compared the BTA (bladder tumor antigen) stat test with the BTA TRAK assay in patients highly suspicious of bladder cancer...
  46. ncbi [Lymph node invasion in prostate cancer]
    Jacques Irani
    Service d'Urologie, , Poitiers, France
    Prog Urol 16:489. 2006
  47. ncbi [Does the initial or secondary status of T1G3 bladder tumours have a prognostic impact?]
    Frédéric Ouaki
    Service d Urologie, Hopital La Miletrie, Poitiers, France
    Prog Urol 16:40-4. 2006
    ..This retrospective study evaluated the prognostic value of the initial or secondary status of pT1G3 bladder tumours...
  48. ncbi Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study
    Jacques Irani
    Department of Urology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
    Eur Urol 54:382-91. 2008
    ..To evaluate systematically interrupted androgen suppression (SIAS) 6 mo a year compared with continuous androgen suppression (CAS) in prostate cancer treatment...
  49. ncbi Fluctuating prostate-specific antigen levels in patients with initial negative biopsy: should we be reassured?
    Olivier Celhay
    Department of Urology, Centre Hospitalier Universitaire La Miletrie, Poitiers, France
    BJU Int 99:1028-30. 2007
    ..To evaluate whether the risk of having a positive repeat prostate biopsy is lower in patients with fluctuating prostate-specific antigen (PSA) levels than in patients with a steady or steadily increasing PSA level...
  50. ncbi [Calculation of PSA doubling time]
    Jacques Irani
    Service d'Urologie, , Poitiers, France
    Prog Urol 16:197. 2006
  51. ncbi Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors
    Laurent Salomon
    Department of Urology, Henri Mondor Hospital, Creteil, France
    Eur Urol 43:39-44. 2003
    ..To analyze the association between Gleason score, stage and status of surgical margins with tumor volume in prostate cancer progression after radical prostatectomy...
  52. ncbi [Active treatment or surveillance in prostate cancer]
    Jacques Irani
    Service d'Urologie, , Poitiers, France
    Prog Urol 17:98. 2007
  53. ncbi Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression
    Olivier Celhay
    Service d Urologie, Centre Hospitalier Universitaire Université de Poitiers, Poitiers, France
    J Urol 184:2172-8. 2010
    ..We investigated the expression of proteins related to androgen and estrogen metabolism in paired prostate cancer samples collected before androgen deprivation therapy and after hormonal relapse...
  54. ncbi Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice
    Francois Desgrandchamps
    Department of Urology, Saint Louis Hospital, Paris, France
    BJU Int 98:83-8. 2006
    ..To assess the improvements in symptoms, quality of life (QoL), discomfort and satisfaction in patients with symptomatic benign prostatic hyperplasia (BPH) treated with dutasteride in clinical practice...
  55. ncbi [Neuroendocrine cancer of the prostate. A series of 6 cases]
    Xavier Breton
    Service d Urologie, CHU La Miletrie, Poitiers, France
    Prog Urol 13:1340-4. 2003
    ..Screening for this tumour, although not systematic, may have therapeutic implications. The authors retrospectively evaluated 6 cases of NECP observed in the department between September 1998 and May 2002...
  56. ncbi [Has the initial or secondary status of the bladder tumors T1 G3 a prognostic impact?]
    Frédéric Ouaki
    Service d Urologie, Hopital La Miletrie, Poitiers, France
    Prog Urol 15:1316-21. 2005
  57. ncbi The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use
    Pierre Teillac
    Hopital St Louis, Paris, France
    Clin Ther 27:273-85. 2005
    ..Investigators continue to explore the use of hormone therapy, particularly luteinizing hormone-releasing hormone (LHRH) analogues, earlier in the course of disease...
  58. ncbi Are all alpha-blockers created the same?
    Jacques Irani
    Eur Urol 49:420-2. 2006
  59. ncbi Infective endocarditis after transrectal prostatic biopsy
    France Roblot
    Department of Internal Medicine, University Hospital, La Miletrie, Poitiers, France
    Scand J Infect Dis 34:131. 2002
    ..Enterococcus faecalis was isolated in blood and urine cultures. This case suggests that infective endocarditis can be associated with transrectal procedures...
  60. ncbi [Urothelial tumors induced by chemotherapy and radiotherapy]
    Jacques Irani
    Prog Urol 13:1232. 2003
  61. ncbi [Prevalence of osteoporotic fractures in patients treated by androgen blockade for prostate cancer]
    Laurent Dahmani
    Service d Urologie, Hopital d Instruction des Armees Sainte Anne, Boulevard Sainte Anne, 83000 Toulon
    Prog Urol 13:73-8. 2003
    ..Hypogonadism induced by chemical castration can be responsible for osteoporosis that may be complicated by fractures...
  62. ncbi [Prostate cancer screening]
    Arnauld Villers
    Prog Urol 13:209-14. 2003
    ..Information concerning the limits, benefits and risks of screening and the available treatment options must be given before performing these examinations...
  63. ncbi [Epidemiology of bladder cancer]
    Jacques Irani
    Prog Urol 13:1207-8. 2003
  64. ncbi [Methodology of recommendations]
    Jacques Irani
    Prog Urol 17:1022-3. 2007
  65. ncbi [Methodology of recommendations]
    Jacques Irani
    Prog Urol 14:877-8. 2004
  66. ncbi [Management of bladder cancer associated with prostate cancer]
    Jean Louis Bonnal
    Comité Tumeurs urothéliales du C C A F U, Roubaix, France
    Prog Urol 13:1286-9. 2003
    ..The diagnostic and treatment options are proposed for each situation, but evidence-based recommendations cannot be proposed on the basis of the published data...
  67. ncbi [Current role of chemotherapy in the treatment of hormone-resistant prostatic cancer]
    Michel Soulie
    Prog Urol 16:394-5. 2006
  68. ncbi [Urothelial tumors]
    Jacques Irani
    Prog Urol 17:1065-98. 2007